"Today's authorization provides an additional COVID-19 vaccine option," said Peter Marks, director of the FDA's Center for Biologics ... 2024-25 COVID-19 vaccines. Novavax's traditional protein ...

The newly approved vaccine targets multiple circulating variants, promising enhanced protection and availability across ...

For many, Novavax is #1 – the one and only COVID vaccine they would consider. This enthusiasm for Novavax isn’t new. As far back as 2022, news reports described a kind of Novavax fan club – a term ...

The Food and Drug Administration (FDA) granted emergency use authorization for an updated version of the Novavax COVID-19 ...

Friday, the FDA granted Emergency Use Authorization to Novavax Inc.’s (NASDAQ:NVAX) COVID-19 Vaccine, Adjuvanted (2024-2025 ...

Unlike Pfizer/BioNTech and Moderna, Novavax does not use mRNA technology for its COVID-19 vaccine, instead opting for a ...

The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.

The protein-based shot represents a non-mRNA option for the 2024-2025 season, and follows the agency's recent approvals and ...

The U.S. Food and Drug Administration on Friday granted emergency use authorization for an updated version of Novavax's COVID ...

The US regulatory agency has also approved updated versions of Moderna and Pfizer / BioNTech’s Covid-19 vaccines in the past ...

The Food and Drug Administration (FDA) has authorized the emergency use of the Novavax COVID-19 Vaccine, Adjuvanted.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.